Skip Navigation
Skip to contents

Diabetes Metab J : Diabetes & Metabolism Journal

Search
OPEN ACCESS

Search

Page Path
HOME > Search
1 "Chu Lin"
Filter
Filter
Article category
Keywords
Publication year
Authors
Funded articles
Review
Type 1 Diabetes
Non-Insulin Antidiabetes Treatment in Type 1 Diabetes Mellitus: A Systematic Review and Meta-Analysis
Xiaoling Cai, Chu Lin, Wenjia Yang, Lin Nie, Linong Ji
Diabetes Metab J. 2021;45(3):312-325.   Published online March 15, 2021
DOI: https://doi.org/10.4093/dmj.2020.0171
  • 6,324 View
  • 274 Download
  • 5 Web of Science
  • 5 Crossref
Graphical AbstractGraphical Abstract AbstractAbstract PDFSupplementary MaterialPubReader   ePub   
In order to evaluate the efficacy and side effects of the non-insulin antidiabetes medications as an adjunct treatment in type 1 diabetes mellitus (T1DM), we conducted systematic searches in MEDLINE, Embase, and the Cochrane Central Register of Controlled Trials for randomized controlled trials published between the date of inception and March 2020 to produce a systematic review and meta-analysis. Overall, 57 studies were included. Compared with placebo, antidiabetes agents in adjunct to insulin treatment resulted in significant reduction in glycosylated hemoglobin (weighted mean difference [WMD], –0.30%; 95% confidence interval [CI], –0.34 to –0.25%; P<0.01) and body weight (WMD, –2.15 kg; 95% CI, –2.77 to –1.53 kg; P<0.01), and required a significantly lower dosage of insulin (WMD, –5.17 unit/day; 95% CI, –6.77 to –3.57 unit/day; P<0.01). Compared with placebo, antidiabetes agents in adjunct to insulin treatment increased the risk of hypoglycemia (relative risk [RR], 1.04; 95% CI, 1.01 to 1.08; P=0.02) and gastrointestinal side effects (RR, 1.99; 95% CI, 1.61 to 2.46; P<0.01) in patients with T1DM. Compared with placebo, the use of non-insulin antidiabetes agents in addition to insulin could lead to glycemic improvement, weight control and lower insulin dosage, while they might be associated with increased risks of hypoglycemia and gastrointestinal side effects in patients with T1DM.

Citations

Citations to this article as recorded by  
  • Prescribing patterns of adjunctive therapy for the treatment of type 1 diabetes mellitus among Australian endocrinologists
    Patrice Forner, Jennifer Snaith, Jerry R. Greenfield
    Internal Medicine Journal.2024; 54(5): 779.     CrossRef
  • Dioscin: Therapeutic potential for diabetes and complications
    Haoyang Gao, Ze Wang, Danlin Zhu, Linlin Zhao, Weihua Xiao
    Biomedicine & Pharmacotherapy.2024; 170: 116051.     CrossRef
  • The Impact of Body Mass Index, Residual Beta Cell Function and Estimated Glucose Disposal Rate on the Development of Double Diabetes and Microvascular Complications in Patients With Type 1 Diabetes Mellitus
    Rameez Raja Bhagadurshah, Subbiah Eagappan, Raghavan Kasthuri Santharam, Sridhar Subbiah
    Cureus.2023;[Epub]     CrossRef
  • Type 1 diabetes glycemic management: Insulin therapy, glucose monitoring, and automation
    Bruce A. Perkins, Jennifer L. Sherr, Chantal Mathieu
    Science.2021; 373(6554): 522.     CrossRef
  • Current Advances of Artificial Pancreas Systems: A Comprehensive Review of the Clinical Evidence
    Sun Joon Moon, Inha Jung, Cheol-Young Park
    Diabetes & Metabolism Journal.2021; 45(6): 813.     CrossRef

Diabetes Metab J : Diabetes & Metabolism Journal